Research Support Centre
Technology Platforms
Tech Access Symposium Page Header 23Nov

Enabling Your Research with Tech Access


Gaining access to the right equipment, service platform and expertise for the job can sometimes present a challenge for local SMEs. The Tech Access Initiative aims to support companies’ innovation efforts by providing access to a comprehensive suite of A*STAR’s advanced manufacturing and biomedical scientific instrumentation, supported by skilled technology experts. Through this initiative, eligible SMEs are provided a cost-effective way to meet their research goals under the guidance of qualified experts.

Jointly organised by Research Support Centre and Tech Access Office, this inaugural Tech Access virtual Symposium focuses on some key areas, from amongst a selection of Biotech/Biomedical scientific services and equipment available under this initiative.

Bringing together highly knowledgeable field experts, the symposium will feature topics from biopharmaceutical testing (pharmacokinetic studies), histology processing, mass spectrometry and virucidal testing, to cutting-edge spatial profiling technologies.

We will also share about the enhanced funding support at 80%* of qualifying project costs for eligible local SMEs tapping on Tech Access.

Come Join Us! Register for this free Symposium today!


*Terms & Conditions apply

Tech Access Symposium subheader Registration-06



Tech Access Symposium- Flyer v3







Click here to register!



Tech Access Symposium subheader Programme_w


Opening Address

Ms Annabelle Pang,

Manager, Business Development, Research Support Centre, A*STAR


Ms Belinda Owen,

Tech Access Office, A*STAR


Spatial Technologies to study immune microenvironment: When COVID-19 meet the immune-oncology


10min Question & Answer

Dr Joe Yeong, MBBS, PhD, Mmed (Pathology)

Group Leader Integrative Biology for Theranostics Lab, A*STAR IMCB

Department of Anatomical Pathology, SGH


Biopharma Innovations and Solutions – One-stop support for local start-ups and academia


10min Question & Answer

Dr. Lakshmanan Manikandan, PhD

Group Leader, Biopharma Innovation Solutions, A*STAR IMCB


Advanced Molecular Pathology Laboratory (AMPL) – How can we help you?


10min Question & Answer

Dr. Ravisankar Rajarethinam, MVSc, PhD (Vet Path), DABT

Senior Group Leader, Advanced Molecular Pathology Laboratory (AMPL), A*STAR IMCB


Lucky Draw




Introduction to A*STAR mass spectrometry capabilities for cutting edge analytical support provided to academics and industry community


10min Question & Answer

Dr. Radoslaw Sobota, PhD

Principal Investigator, Functional Proteomics Laboratory, A*STAR IMCB

Founding Member of Singapore National Laboratory for Mass Spectrometry (SingMass), NRF-SIS

High content in-situ spatial profiling technologies – DSP and IMC capabilities and translational applications


10min Question & Answer

Dr. Akhila Balachander, PhD

Scientific Lead, Spatial Immunophenomics platform, A*STAR SIgN


Virucidal Evaluation and Efficacy Testing


10min Question & Answer

Ms Regina Lee,

Research Associate, Collaborative and Translational Unit for Hand, Foot and Mouth Disease (HFMD), A*STAR IMCB, National University of Singapore


Lucky Draw





Tech Access Symposium subheader Speakers_w

Lakshmanan Manikandan

Dr. Lakshmanan Manikandanis a translational pharmacologist by training and has more than 18 years of Drug Discovery experience in various pharmaceutical companies such as Forma Therapeutics, Syngene International Limited, Ranbaxy Research Laboratories (acquired by Daiichi Sankyo). He has published more than 45 research articles and has been awarded 5 patents with two of the molecules currently in Phase I/II clinical trials. He was also a part of a team (Forma Therapeutics) that out-licensed a tumor metabolism program to Genentech. He has been instrumental in setting up Joint lab with Indivumed (The Cancer Library Initiative), Germany and in vitro alternative to animal testing (GLP) platform in IMCB.

Ravisankar Rajarethinam

Dr. Ravisankar Rajarethinam worked as a lead scientist for more than 15 years in efficacy as well as toxicity testing of new chemical entities and biologicals in well-known Pharmaceutical companies such as Glenmark Pharma, Ranbaxy and Biocon in India. At present, Dr. Ravi works as research veterinary pathologist and study director for GLP graded toxicology studies and oversees the laboratory management and activities. He has obtained training in Descriptive Veterinary Pathology at University of Queensland, Australia and in vitro toxicology at IIVS, Inc., USA. His professional contribution is published in high impact peer-reviewed journals.

Dr. Joe Yeong’s main research focus is to understand and overcome the resistance of immunotherapy. As an immuno-pathologist, his key vision is to bridge between immunologists and pathologists. He has published > 80 papers in this field. His works are included in multiple NMRC studies as well as pharm sponsored projects (>5 million dollars since 2017). He also served as a committee member in the World Immunotherapy Council, Society for Immunotherapy of Cancer (SITC) and is one of the organizers for 2021 expert consensus meeting of multiplex IHC/IF. 

Asset 3@2x

Dr. Radoslaw Sobota received his PhD from Rheinisch-Westfälische Technische Hochschule Aachen (RWTH-Aachen), Germany, in 2007. The following year, he joined the Centre for Experimental Bioinformatics group at the University of Southern Denmark in Odense, continuing his scientific career with Jens Andersen. In 2012, he joined A*STAR’s Singapore Immunology Network (SIgN) where he applied cutting-edge mass spectrometry-based proteomics in advanced immunology. Subsequently, he joined A*STAR’s Institute for Molecular and Cell Biology (IMCB). Since 2018 he is heading Functional Proteomics Laboratory Group at IMCB, in 2019 his laboratory was awarded with National Research Foundation (NRF-SIS) grant as a founding member of Mass spectrometry National Laboratory (SingMass) in Singapore together with National University of Singapore. He is a member of steering committee and board of directors.

Dr. Akhila Balachander is the scientific lead setting up and driving spatial profiling technologies at the Singapore Immunology Network (SIgN), A-STAR. She is a cell biologist by training and has obtained her doctorate degree from the Max-Planck Institute of Cell Biology and Genetics, Dresden, Germany. After a brief post-doctoral stint at SIgN, she moved on to technology development and facility management. She has since been instrumental in developing various imaging-based technologies at SIgN. She is now setting up two important high content spatial technologies, viz. Imaging Mass Cytometry and Digital Spatial profiling that will be discussed in this symposium.

Ms. Regina Lee is a Research Associate in A/Prof Justin Chu’s laboratory. She specialises in molecular virology techniques. Additionally, she performs antiviral drug screening assays, anti-virucidal testing with external companies and internal collaborators.



Tech Access Symposium separator-05